Replimune Group, Inc.
REPL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001737953
In the last 90 days, Replimune Group, Inc. insiders filed 0 open-market purchases and 3 sales; 200 institutions reported holding it in 13F filings for Q2 2026, worth $1.06B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 11, 2026
- $2.06B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $654.0K in total
- 3
- 13F holdersQ2 2026, +19 vs. previous quarter
- 200
- 13F valueReported value at the end of Q2 2026
- $1.06B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2026
- –
- No comparable prior period
- Net income, FY2026
- -$313.9M
- No comparable prior period
- Free cash flow, FY2026
- -$284.6M
- No comparable prior period
- Revenue, Q2 FY2027
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 24.6M
- Shares sold short
- Change
- +1.44M
- +6.2% vs. previous
- Days to cover
- 8.31
- At average daily volume
Superinvestors holding REPL, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding REPL at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Replimune Group, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 10, 2026 (view filing)4:30 PM ET | Nov 9 | 1 day | Slattery Joseph PDirector | SSale | −5.20K | $21.80 | −$113.4K | −78.0%1.47K after | |
| Nov 3, 2026 (view filing)8:43 PM ET | Nov 2 | 1 day | Dhingra KapilDirector | SSale | −21.5K | $19.00 | −$408.5K | −49.8%21.7K after | |
| Aug 19, 2026 (view filing)6:42 PM ET | Aug 17 | 2 days | Hill Emily LuisaChief Financial Officer | SSale | −9.26K | $14.28 | −$132.2K | −4.1%215.9K after | |
| Aug 12, 2026 (view filing)5:07 PM ET | Aug 10 | 2 days | Patel SushilChief Executive Officer | SSale | −39.3K | $12.97 | −$510.3K | −5.3%708.2K after | |
| Aug 12, 2026 (view filing)5:06 PM ET | Aug 10 | 2 days | Hill Emily LuisaChief Financial Officer | SSale | −11.4K | $12.97 | −$148.5K | −4.8%225.1K after | |
| Aug 12, 2026 (view filing)5:05 PM ET | Aug 10 | 2 days | Xynos KonstantinosChief Medical Officer | SSale | −11.4K | $12.97 | −$148.5K | −4.9%224.2K after | |
| Aug 12, 2026 (view filing)5:04 PM ET | Aug 10 | 2 days | Schwendenman AndrewChief Accounting Officer | SSale | −7.63K | $12.97 | −$99.0K | −7.1%99.4K after | |
| Aug 11, 2026 (view filing)5:46 PM ET | Aug 11 | Same day | Baker Julian and 5 othersDirector, 10% Owner | PPurchase | +2.74M | $12.06 | +$33.0M | –2.61M after | Derivative2 lots |
| Jun 3, 2026 (view filing) | Jun 1 | 2 days | Sarchi ChristopherChief Commercial Officer | SSale | −12.0K | $9.24 | −$110.9K | −6.2%181.0K after | 10b5-1 |
| May 20, 2026 (view filing) | May 18 | 2 days | Xynos KonstantinosChief Medical Officer | SSale | −14.0K | $5.08 | −$71.2K | −5.6%235.7K after |
Top 10 13F holders, Q2 2026
See all 200 holdersThe largest institutional positions in Replimune Group, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 11,045,336 | $122.3M | 0.61% | 00.0% | Unchanged |
| BlackRock, Inc. | 8,958,535 | $99.2M | 0.00% | +2,719,296+43.6% | Added |
| RTW Investments, LP | 7,411,581 | $82.0M | 0.70% | +54,665+0.7% | Added |
| Ridgeback Capital Investments L.P. | 7,310,656 | $80.9M | 100.00% | +7,310,656 | New |
| Goldman Sachs Group Inc | 4,541,018 | $50.3M | 0.01% | +2,263,742+99.4% | Added |
| State Street Corp | 4,440,144 | $49.2M | 0.00% | +657,907+17.4% | Added |
| Suvretta Capital Management, LLC | 4,389,836 | $48.6M | 1.02% | +168,000+4.0% | Added |
| Boxer Capital Management, LLC | 3,983,000 | $44.1M | 3.32% | +2,808,000+239.0% | Added |
| Vanguard Capital Management LLC | 2,896,004 | $32.1M | 0.00% | +136,884+5.0% | Added |
| FCPM III Services B.V. | 2,808,368 | $31.1M | 4.14% | 00.0% | Unchanged |
Holders of 5% or more of REPL
See all 4 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Replimune Group, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 13D/A | 11.80%11.1M shares | −2.50 ppfrom 14.30% | Feb 14, 20235 filings | Aug 11, 2026 | SEC |
| RTW Investments, LP | 13G/A | 8.90%7.36M shares | +0.70 ppfrom 8.20% | Nov 14, 20252 filings | May 15, 2026 | SEC |
| Ridgeback Capital Investments L.P. | 13G/A | 8.70%7.31M shares | +1.10 ppfrom 7.60% | May 21, 20262 filings | Aug 14, 2026 | SEC |
| Suvretta Capital Management, LLC | 13G/A | 7.90%6.61M shares | +2.80 ppfrom 5.10% | May 12, 20262 filings | Aug 6, 2026 | SEC |